Electronics maker Qisda Corp (佳世達) and TCI Co (大江生醫), which manufactures health food, functional beverages and skincare products, on Friday said that they would form a strategic alliance through a private placement.
Under the deal, Qisda plans to acquire 4.72 million shares in a TCI subsidiary, TCI Gene Inc (大江基因), at NT$115.5 per share, the company’s regulatory filing showed on Friday.
TCI Gene is mainly engaged in the research and manufacturing of various genetic testing, stem cell and immune cell products.
Photo: Chen Mei-ying, Taipei Times
The NT$545.16 million (US$18.38 million) investment would allow Qisda to hold a 17.84 percent stake in TCI Gene, using its own capital to fund the deal, the filing said.
“To strengthen the company’s biotechnology business, Qisda has stepped into the field of precision medicine,” the company said in the filing. “Through this investment, we will complement each other’s resources, expand the biotechnology and medical care business, and provide customers with a wider range of products and services.”
Qisda manufactures computer accessories, communication devices and consumer electronics. It also provides consulting and technical services, and has cultivated a high-value-added medical business, which has been the firm’s best performer during the COVID-19 pandemic.
Precision medicine is an emerging model in which precise detection prevents diseases in their early stages, and treats them with specific medicines. The practice provides treatment that most accurately minimizes adverse drug reactions and avoids wasting medical resources, it said.
A PricewaterhouseCoopers report on the precision health industry said that the market is forecast to grow from US$68.3 billion in 2020 to US$134.4 billion in 2025, with a compound annual growth rate of 14 percent.
The genetic testing market, which is the basis of precision medicine, has attracted much attention, Qisda said.
The market potential for this segment is predicted to grow from US$8 billion last year to US$15.8 billion in 2030, with compound growth of 7.6 percent, it said, citing data from Precedence Research.
The application of cell therapy in precision medicine should also have high growth potential, it added.
Precision medicine is an emerging business suitable for technology firms, as it is expected to integrate new technologies such as genetic testing, immune cell therapy and artificial intelligence, Qisda chairman Peter Chen (陳其宏) said.
“We look forward to providing more accurate preventive medicine, precise diagnosis and treatment services to the public through cooperation with TCI Group (大江生醫集團),” Chen said in a statement.
TCI Group chairman Vincent Lin (林詠翔) said he expects to leverage the strength of Qisda in medical services, equipment, pharmaceutical access and big data solutions to increase TCI Gene’s products and testing services.
Cairo’s new monorail slices across the city skyline, running above the familiar chaos of blaring horns and aging buses’ exhaust fumes that mark rush hour below. The US$4.5 billion monorail, opened this month, is among Egypt’s most prominent new transport projects, part of a debt-funded infrastructure drive criticized for sapping state finances while bringing limited benefits to most of the country’s 109 million people. “It feels like you’re in a different country,” said Ramy Sayed, a restaurant manager, aboard a driverless Innovia 300 train. “No noise, no traffic, we’re not used to this.” The eastern line runs 56km from the bustling middle-class
Taiwanese firms have increased investment in the Philippines in recent years as Manila’s ties with Washington deepen and global supply chains continue to shift away from China, an expert at the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The Philippines had not been among Taiwanese investors’ top choices in Southeast Asia, CIER Taiwan ASEAN Studies Center director Kristy Hsu (徐遵慈) said at a seminar in Taipei. However, Taiwan’s investment in the country has grown significantly since the COVID-19 pandemic, reaching US $257 million last year, a high in recent years, she said. Although Taiwan’s total investment in the Philippines still lags
Starlux Airlines Co (星宇航空) today unveiled a long-haul network expansion plan at a shareholders’ meeting in Taipei, including direct flights to Barcelona, Spain, and Zurich, Switzerland, as well as a service connecting Taipei, Sydney and New Zealand. Starlux is to become the first Taiwanese carrier to offer non-stop services to the two European cities, while the inaugural oceanic route is expected to expand transit opportunities within the Australia-New Zealand market, Starlux said. Flight services to Chicago, Dallas, Washington and New York are under evaluation, the airline added. Prior to the shareholders’ meeting, the airline earlier this year announced that it would be
Intel Corp regards Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) as a longstanding partner, as the US chipmaker would continue outsourcing production of advanced chips to TSMC, Intel chief executive officer Lip-Bu Tan (陳立武) said yesterday. “I don’t look at people as competitors. I look at the collaboration... Nvidia is also, you know, a good friend,” Tan told a news conference following his keynote speech at the Computex trade show in Taipei. “It’s a very trusted partnership for us... We are a big, top customer for them, and we’re going to continue doing that,” he said, referring to TSMC, the world’s largest foundry
RSS